<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>32163</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_doi">10.1186/1471-2326-1-2</infon><infon key="article-id_pmc">32163</infon><infon key="article-id_pmid">11319038</infon><infon key="article-id_publisher-id">1471-2326-1-2</infon><infon key="fpage">2</infon><infon key="journal-title">BMC Blood Disorders</infon><infon key="lpage">2</infon><infon key="name_0">surname:Stanulla;given-names:Martin</infon><infon key="name_1">surname:Schrauder;given-names:Andr&#233;</infon><infon key="name_2">surname:Welte;given-names:Karl</infon><infon key="name_3">surname:Schrappe;given-names:Martin</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">1</infon><infon key="year">2001</infon><offset>0</offset><text>Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapy</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>204</offset><text>What is the background on this?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>215</offset><text>The outcome of solid and hematologic malignancies has been linked to elevated levels of tumor necrosis factor (TNF) and lymphotoxin- (LT-2) in the circulatory system. Polymorphisms have been identified within the TNF gene and its variant alleles, known as those of the LT-10.5 kb and 5-HT2 gene, respectively.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>984</offset><text>Techniques</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>992</offset><text>A case-control study was conducted on 64 individuals with non-relapsed childhood B-cell precursors who had been treated for remission and 64 successfully.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1172</offset><text>What are the outcomes?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1180</offset><text>Relative to the overall category of TNF1/TNF2 genotype, the OR was 1.17 (95 % confidence interval (CI) = 0.53 - 2.56, P = 0.697) for the combined category; however, with respect to that of the LT- (10.5 kb/10.5 Kb) genotyp E,OR was calculated as 2.17 (95% chance of finding a positive test set at 95% confidence rate; P=0.001) and p=0.38 (100% probability of discovering the undiscovered testing) in relation to this particular genotyping.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1616</offset><text>Remarkable conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1628</offset><text>The study indicates that the genetic polymorphisms studied in childhood B-cell precursor ALL treated with BFM protocols do not have a significant impact on risk of relapse.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1843</offset><text>Tumor necrosis factor and lymphotoxin-alpha (TNF-alpha) are two classes of immune cells that produce cytokines that are involved in the immune response to foreign invaders, such as viruses. In children, these cytokines are produced by B-cells and are known to play a role in the development of B-cell precursors of acute lymphoblastic leukemia (ALL).

The incidence of childhood ALL is increasing in the UK, and the number of children with the condition is on the rise, with an estimated 7% of children having the disease by the age of 20 in the UK, which is double the number of children with ALL in 1974</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1854</offset><text>The secretion of TNF and lymphotoxin-, with pleiotropic biological activities, has been associated with the outcome of certain autoimmune and infectious diseases, as well as solid and hematologic malignancies.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3478</offset><text>In this study, we genotyped a group of 64 patients with childhood acute lymphoblastic leukemia (ALL) in both matched case-control studies and identified genetic polymorphisms within TNF and LT- genes to determine their predictive power for ALL relapse.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>3809</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>3817</offset><text>Patients and study design</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>3843</offset><text>The present study utilizes patients and data from the ALL-BFM 86 and ALL-BFM 90 multicenter trials of childhood ALL, conducted by the BFM study group. Design, conduct, analysis, and results of the ALL-BFM 86 and ALL-BFM 90 trials are described in detail elsewhere. In both trials treatment was stratified into three branches (standard, intermediate, and high risk), mainly according to the leukemic cell mass estimate and treatment response. Treatment (in most cases induction, consolidation, reinduction, maintenance) consisted of intensive multiagent chemotherapy regimens employing standard drugs (e.g. prednisone, vincristin, daunorubicin, L-asparaginase, cyclophosphamide, cytarabine, 6-mercaptopurine, 6-thioguanin, methotrexate). Parts of the study group received cranial radiotherapy.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4636</offset><text>The establishment of the present case-control study group has been described previously. Briefly, relapsed patients from ALL-BFM 86 and ALL-BFM 90 with an available remission peripheral blood or bone marrow smear were included as cases into the study group if they could be matched to a successfully treated patient with an available remission peripheral blood or bone marrow smear (control individual) according to the following criteria: sex, age at diagnosis (&#177; 6 months), white blood cell count (WBC) at diagnosis (&#177; 10,000/&#956;l), immunophenotype, trial, risk group, and treatment arm within the risk group of the respective trial. The latter criterion assured similarity of treatment between cases and controls. Controls had to have a minimum follow-up of 5 years. In case of relapses occurring later than 5 years of diagnosis, the follow-up for the control subject had to be at least as long as the time from date of initial diagnosis to date of relapse diagnosis in the case subject. If more than one control subject was available, the subject with the closest initial WBC at diagnosis with reference to the case subject was chosen. All spare remission peripheral blood or bone marrow smears were derived from official routine remission control examinations at time points during the first 6 month of treatment according to the study protocols of ALL-BFM 86 and 90.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6010</offset><text>Genotype analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6028</offset><text>Genomic DNA was isolated from remission bone marrow or peripheral blood smears as described before. Genotypes for TNF and LT-&#945; were determined by polymerase chain reaction (PCR)-based restriction fragment length polymorphism (RFLP) analysis. The -308 TNF promoter polymorphism was analyzed by incorporating it into an Ncol restriction site that was created by introducing a single base change within the forward primer. Primer sequences were: forward 5'-AGGCAATAGGTTTTGAGGGCCAT-3'; reverse 5'-TCCTCCCTGCTCCGATTCCG-3'. The LT-&#945; polymorphism at nucleotide position +252 was analyzed by PCR amplification of a 368 bp fragment using the following primer pair: forward 5'-CTCCTGCACCTGCTGCCTGGATC-3'; reverse 5'-GAAGAGACGTTCAGGTGGTGTCAT-3'. The amplified PCR products were digested overnight with Ncol and analyzed on 3.0 % Nusieve (TNF) or 3.0 % conventional agarose gels (LT-&#945;). In case of presence of the TNF1 allele, the amplified 107 bp fragment from the TNF promoter is cut into two fragments of 87 and 20 bp, a fragment amplified from TNF2 remains uncut. The 368 bp fragment from LT-&#945; is unaffected by Ncol digestion in case of presence of a LT-&#945; (10.5 kb) allele while a PCR product amplified from a LT-&#945; (5.5 kb) allele is cut into two fragments of 133 and 235 bp.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7320</offset><text>Statistical analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7341</offset><text>After frequencies were calculated for descriptive purposes, correlation analyses (contigency coefficients for nominal data, Spearman correlation coefficients for ordinal data, Pearson correlation coefficients for continous data) were computed to investigate the interrelationships between TNF genotype, LT-&#945; genotype and important clinical prognostic variables such as sex, age at diagnosis, WBC at diagnosis, and immunophenotype. Differences in the distribution of categorical variables were analyzed by &#935;2 or Fisher's exact test. The association between TNF and LT-&#945; genotypes and relapse of leukemia was examined by use of conditional logistic regression analysis to calculate odds ratios and their 95 % confidence intervals. Genotypes and genotype combinations were used as categorical variables in the analyses. The association of genotypes with time to relapse was analyzed by log rank tests. Computations were peformed using SAS software (SAS-PC Version 6.04, SAS Institute Inc., Cary, NC).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>8349</offset><text>Results and Discussion</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>8372</offset><text>Table 1 shows the distribution of matching variables and genetic analyses (DNA index and karyotype) in the 64 relapsed case subjects and the 64 successfully treated control subjects as previously described. Within our entire study population of 128 patients, 84 (65.6%) patients were homozygous for the TNF1 allele, 41 (32.0%) patients were heterozygous (TNF1/TNF2) and 3 (2.3%) patients were homozygous for the TNF2 allele. With regard to LT-&#945;, we observed 55 (43.0%) patients being homozygous for the LT-&#945; (l0.5 kb) allele and 55 (43.0%) patients being heterozygous (LT-&#945; (10.5 kb)/ LT-&#945; (5.5 kb)). Eighteen (14.1%) patients were homozygous for the LT-&#945; (5.5 kb) allele. The prevalences observed in our study are similar to the ones reported by Demeter et al. in a healthy German control sample. Thus, it seems unlikely that TNF or LT-&#945; genotypes are associated with the pathogenesis of childhood B-cell precursor ALL in the German population. With regard to clinically important variables, no particular associations between the TNF and LT-&#945; genotypes and sex, age at diagnosis, WBC at diagnosis, immunophenotype, and risk group were observed (data not shown). Table 2 shows the prevalences of the investigated TNF and LT-&#945; genotypes by case-control status of our study subjects. In addition, Table 2 contains information on the association of the -308 TNF promoter polymorphism and the intronic LT-&#945; polymorphism at nucleotide position 252 with risk of ALL relapse in our study subjects. For both genotypes, no particular associations with risk of ALL relapse were observed (Table 2). As reported in previous studies, the TNF1 allele was significantly linked to the LT-&#945; (l0.5 kb) allele as was the TNF2 allele to the LT-&#945; (5.5 kb) allele (&#935;2 test; P &lt; 0.01). The strong association between polymorphic TNF and LT-&#945; alleles made Warzocha and colleagues to use haplotypes for their outcome analysis in a study on lymphoma outcome related to TNF and LT-&#945; alleles. In their study, the authors found that the presence of at least two TNF or LT-&#945; high-producer alleles (TNF2 or LT-&#945; (5.5 kb)) was an independent risk factor for progression-free survival in adult diffuse large-cell lymphoma patients. When we analyzed the risk of relapse conferred by so-called high-producer TNF/LT-&#945; haplotypes (at least two high-producer alleles) in comparison to low-producer TNF/LT-&#945; haplotypes (less than two high-producer alleles) we also failed to observe any meaningful association in our study population (odds ratio (OR) = 1.08; 95% confidence interval (CI) = 0.51 - 2.30; P = 0.841). However, based on the discordant pairs observed in our study, we only had a power of 80% to detect risks greater than 3.0 conferred by the TNF1/TNF2 and the LT-&#945; (10.5 kb)/LT-&#945; (5.5 kb) genotypes or by the high-producer TNF/LT-&#945; haplotypes. Therefore, we neither can exclude smaller effects on treatment outcome mediated by the above mentioned exposures nor reasonably exclude clinically important effects of the rare TNF2/TNF2 or the LT-&#945; (5.5 kb)/ LT-&#945; (5.5 kb) genotype. Furthermore, we investigated possible influences of the analyzed TNF and LT-&#945; genotypes on time to relapse or on site of ALL relapse (isolated bone marrow relapse; combined and isolated CNS relapse; combined and isolated testis relapse) and, as above, did not detect any associations.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>11802</offset><text>Characteristics of 64 relapsed case subjects and 64 successfully treated matched control subjects with acute lymphoblastic leukemia selected from trials ALL-BFM 86 and ALL-BFM 90</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center"&gt;&lt;bold&gt;Cases (%)&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;bold&gt;Controls (%)&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;Trial&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;ALL-BFM 86&lt;/td&gt;&lt;td align="center"&gt;35 (54.7)&lt;/td&gt;&lt;td align="center"&gt;35 (54.7)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;ALL-BFM 90&lt;/td&gt;&lt;td align="center"&gt;29 (45.3)&lt;/td&gt;&lt;td align="center"&gt;29 (45.3)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Sex&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;Male&lt;/td&gt;&lt;td align="center"&gt;42 (65.6)&lt;/td&gt;&lt;td align="center"&gt;42 (65.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;Female&lt;/td&gt;&lt;td align="center"&gt;22 (34.4)&lt;/td&gt;&lt;td align="center"&gt;22 (34.4)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Age (y)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;&amp;lt;1&lt;/td&gt;&lt;td align="center"&gt;1 (1.6)&lt;/td&gt;&lt;td align="center"&gt;1 (1.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;1-9&lt;/td&gt;&lt;td align="center"&gt;56 (87.5)&lt;/td&gt;&lt;td align="center"&gt;56 (87.5)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;10-14&lt;/td&gt;&lt;td align="center"&gt;6 (9.4)&lt;/td&gt;&lt;td align="center"&gt;7 (10.9)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;15-18&lt;/td&gt;&lt;td align="center"&gt;1 (1.6)&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;WBC&lt;sup&gt;a&lt;/sup&gt; (10&lt;sup&gt;3&lt;/sup&gt;/&#956;l)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;&amp;lt;10&lt;/td&gt;&lt;td align="center"&gt;42 (65.6)&lt;/td&gt;&lt;td align="center"&gt;41 (64.1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;10-&amp;lt;50&lt;/td&gt;&lt;td align="center"&gt;21 (32.8)&lt;/td&gt;&lt;td align="center"&gt;22 (34.4)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;&#8805; 50&lt;/td&gt;&lt;td align="center"&gt;1 (1.6)&lt;/td&gt;&lt;td align="center"&gt;1 (1.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Immunophenotype&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;c-ALL&lt;sup&gt;b&lt;/sup&gt;&lt;/td&gt;&lt;td align="center"&gt;54 (84.4)&lt;/td&gt;&lt;td align="center"&gt;54 (84.4)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;pre-B-ALL&lt;sup&gt;c&lt;/sup&gt;&lt;/td&gt;&lt;td align="center"&gt;10 (15.6)&lt;/td&gt;&lt;td align="center"&gt;10 (15.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Risk group&lt;sup&gt;d&lt;/sup&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;standard&lt;/td&gt;&lt;td align="center"&gt;23 (35.9)&lt;/td&gt;&lt;td align="center"&gt;23 (35.9)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;intermediate&lt;/td&gt;&lt;td align="center"&gt;41 (64.1)&lt;/td&gt;&lt;td align="center"&gt;41 (64.1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;high&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;DNA index&lt;sup&gt;e&lt;/sup&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;&amp;lt;1.16&lt;/td&gt;&lt;td align="center"&gt;30 (46.9)&lt;/td&gt;&lt;td align="center"&gt;30 (46.9)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;&#8805; 1.16&lt;/td&gt;&lt;td align="center"&gt;12 (18.8)&lt;/td&gt;&lt;td align="center"&gt;7 (10.9)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;not examined&lt;/td&gt;&lt;td align="center"&gt;22 (34.4)&lt;/td&gt;&lt;td align="center"&gt;27 (42.2)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Genotype&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;normal&lt;/td&gt;&lt;td align="center"&gt;4 (6.3)&lt;/td&gt;&lt;td align="center"&gt;10 (15.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;11q23 abberations&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;td align="center"&gt;1 (1.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;t(1;19)&lt;/td&gt;&lt;td align="center"&gt;1 (1.6)&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;t(9;22)&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;td align="center"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;other&lt;/td&gt;&lt;td align="center"&gt;15 (23.3)&lt;/td&gt;&lt;td align="center"&gt;13 (20.3)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;not examined&lt;/td&gt;&lt;td align="center"&gt;44 (68.8)&lt;/td&gt;&lt;td align="center"&gt;40 (62.5)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>11981</offset><text>	Cases (%)	Controls (%)	 	Trial			 	&#8195;ALL-BFM 86	35 (54.7)	35 (54.7)	 	&#8195;ALL-BFM 90	29 (45.3)	29 (45.3)	 	Sex			 	&#8195;Male	42 (65.6)	42 (65.6)	 	&#8195;Female	22 (34.4)	22 (34.4)	 	Age (y)			 	&#8195;&lt;1	1 (1.6)	1 (1.6)	 	&#8195;1-9	56 (87.5)	56 (87.5)	 	&#8195;10-14	6 (9.4)	7 (10.9)	 	&#8195;15-18	1 (1.6)	-	 	WBCa (103/&#956;l)			 	&#8195;&lt;10	42 (65.6)	41 (64.1)	 	&#8195;10-&lt;50	21 (32.8)	22 (34.4)	 	&#8195;&#8805; 50	1 (1.6)	1 (1.6)	 	Immunophenotype			 	&#8195;c-ALLb	54 (84.4)	54 (84.4)	 	&#8195;pre-B-ALLc	10 (15.6)	10 (15.6)	 	Risk groupd			 	&#8195;standard	23 (35.9)	23 (35.9)	 	&#8195;intermediate	41 (64.1)	41 (64.1)	 	&#8195;high	-	-	 	DNA indexe			 	&#8195;&lt;1.16	30 (46.9)	30 (46.9)	 	&#8195;&#8805; 1.16	12 (18.8)	7 (10.9)	 	&#8195;not examined	22 (34.4)	27 (42.2)	 	Genotype			 	&#8195;normal	4 (6.3)	10 (15.6)	 	&#8195;11q23 abberations	-	1 (1.6)	 	&#8195;t(1;19)	1 (1.6)	-	 	&#8195;t(9;22)	-	-	 	&#8195;other	15 (23.3)	13 (20.3)	 	&#8195;not examined	44 (68.8)	40 (62.5)	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>12874</offset><text>a white blood cell count b common acute lymphoblastic leukemia c precursor B-cell acute lymphoblastic leukemia d therapy stratification in risk groups was mainly based on initial leukemic cell mass estimate and initial treatment response, e ratio of DNA content of leukemic G0/G1 cells to normal diploid lymphocytes</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>13190</offset><text>Distribution of tumor necrosis factor (TNF) and lymphotoxin-&#945; (LT-&#945;) genotypes and their association with the occurrence of relapse in 64 case subjects and 64 successfully treated matched control subjects with acute lymphoblastic leukemia from ALL-BFM trials 86 and 90</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center"&gt;&lt;bold&gt;Cases (%)&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;bold&gt;Controls (%)&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;OR&lt;sup&gt;a&lt;/sup&gt; (95 % CI&lt;sup&gt;b&lt;/sup&gt;)&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;bold&gt;&lt;italic&gt;P&lt;/italic&gt; value&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;TNF&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;&lt;italic&gt;TNF1/TNF1&lt;/italic&gt;&lt;/td&gt;&lt;td align="center"&gt;41 (64.1)&lt;/td&gt;&lt;td align="center"&gt;43 (67.2)&lt;/td&gt;&lt;td align="left"&gt;1.00&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;&lt;italic&gt;TNF1/TNF2&lt;/italic&gt;&lt;/td&gt;&lt;td align="center"&gt;21 (32.8)&lt;/td&gt;&lt;td align="center"&gt;20 (31.3)&lt;/td&gt;&lt;td align="left"&gt;1.17&lt;sup&gt;c&lt;/sup&gt; (0.53-2.56)&lt;/td&gt;&lt;td align="center"&gt;0.697&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;&lt;italic&gt;TNF2/TNF2&lt;/italic&gt;&lt;/td&gt;&lt;td align="center"&gt;2 (3.1)&lt;/td&gt;&lt;td align="center"&gt;1 (1.6)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;LT-&#945;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;&lt;italic&gt;10.5 kb/10.5 kb&lt;/italic&gt;&lt;/td&gt;&lt;td align="center"&gt;25 (39.1)&lt;/td&gt;&lt;td align="center"&gt;30 (46.9)&lt;/td&gt;&lt;td align="left"&gt;1.00&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;&lt;italic&gt;10.5 kb/5.5 kb&lt;/italic&gt;&lt;/td&gt;&lt;td align="center"&gt;32 (50.0)&lt;/td&gt;&lt;td align="center"&gt;23 (35.9)&lt;/td&gt;&lt;td align="left"&gt;2.17 &lt;sup&gt;d&lt;/sup&gt; (0.84-5.58)&lt;/td&gt;&lt;td align="center"&gt;0.107&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&#8195;&lt;italic&gt;5.5 kb/5.5 kb&lt;/italic&gt;&lt;/td&gt;&lt;td align="center"&gt;7 (10.9)&lt;/td&gt;&lt;td align="center"&gt;11 (17.2)&lt;/td&gt;&lt;td align="left"&gt;0.50 &lt;sup&gt;d&lt;/sup&gt; (0.09-2.66)&lt;/td&gt;&lt;td align="center"&gt;0.418&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>13467</offset><text>	Cases (%)	Controls (%)	ORa (95 % CIb)	P value	 	TNF					 	&#8195;TNF1/TNF1	41 (64.1)	43 (67.2)	1.00		 	&#8195;TNF1/TNF2	21 (32.8)	20 (31.3)	1.17c (0.53-2.56)	0.697	 	&#8195;TNF2/TNF2	2 (3.1)	1 (1.6)			 	LT-&#945;					 	&#8195;10.5 kb/10.5 kb	25 (39.1)	30 (46.9)	1.00		 	&#8195;10.5 kb/5.5 kb	32 (50.0)	23 (35.9)	2.17 d (0.84-5.58)	0.107	 	&#8195;5.5 kb/5.5 kb	7 (10.9)	11 (17.2)	0.50 d (0.09-2.66)	0.418	 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>13847</offset><text>a odds ratio b confidence interval c odds ratio for the combined category of TNF1/TNF2 and TNF2/TNF2 genotypes d odds ratio for the combined category of LT-&#945; (10.5 kb/5.5 kb) and LT-&#945; (5.5 kb/5.5 kb) with reference to LT-&#945; (10.5 kb/10.5 kb) was 1.5 (95% CI = 0.68-3.32; P = 0.317)</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14140</offset><text>From the data presented in this study, we are not able to generalize our findings to childhood ALL patients of all immunophenotypic subgroups since we only investigated common and pre-B-cell ALLs. Similarly, we were not able to assess an association of the investigated TNF and LT-&#945; genotypes on risk of relapse in high-risk childhood ALL patients since also these patients were not part of our study group. The latter point may be interesting to pursue as Demeter and colleagues, in a study on TNF and LT-&#945; polymorphisms in chronic lymphocytic leukemia (CLL), detected an increase of the LT-&#945; (10.5 kb) allele at more advanced disease stages. Thus, additional investigations including childhood ALL patients of all clinically relevant subgroups are needed to lead to more conclusive results. However, for the subgroup of childhood B-cell precursor ALL of standard and intermediate risk treated according to BFM regimens that was analyzed in the present study, the investigated genetic TNF and LT-&#945; polymorphisms do not seem to play a major role with regard to risk of relapse.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>15234</offset><text>Remarkable conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>15246</offset><text>The TNF gene polymorphism at nucleotide position -308 and the LT- gene PolymorphISm (Pg) at Pg 252 were not significantly associated with ALL relapse in a matched case-control group of 64. childhood B-cell precursor ALL patients, all of which were either standard or intermediate risk; our study showed that these genetic poly(h)istromeromes had little to no effect on the risk of recidivism among those who were followed by BFM protocols.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>15792</offset><text>Competing interests</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>15812</offset><text>None declared.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>15827</offset><text>Pre-publication history</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>15851</offset><text>The pre-publication history for this paper can be accessed here:</text></passage><passage><infon key="fpage">1717</infon><infon key="lpage">1725</infon><infon key="name_0">surname:Bazzoni;given-names:F</infon><infon key="name_1">surname:Beutler;given-names:B</infon><infon key="pub-id_doi">10.1056/NEJM199606273342607</infon><infon key="pub-id_pmid">8637518</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">334</infon><infon key="year">1996</infon><offset>15916</offset><text> The tumor necrosis factor ligand and receptor families.</text></passage><passage><infon key="fpage">83</infon><infon key="lpage">96</infon><infon key="name_0">surname:Warzocha;given-names:K</infon><infon key="name_1">surname:Bienvenu;given-names:J</infon><infon key="name_2">surname:Coiffier;given-names:B</infon><infon key="name_3">surname:Salles;given-names:G</infon><infon key="section_type">REF</infon><infon key="source">Eur Cytokine Network</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">1995</infon><offset>15973</offset><text> Mechanism of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.</text></passage><passage><infon key="fpage">2451</infon><infon key="lpage">2458</infon><infon key="name_0">surname:Dosquet;given-names:C</infon><infon key="name_1">surname:Coudert;given-names:MC</infon><infon key="name_2">surname:Lepage;given-names:E</infon><infon key="name_3">surname:Cabane;given-names:J</infon><infon key="name_4">surname:Richard;given-names:F</infon><infon key="pub-id_pmid">9815646</infon><infon key="section_type">REF</infon><infon key="source">Clin Cancer Res</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">1997</infon><offset>16063</offset><text> Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?</text></passage><passage><infon key="fpage">2357</infon><infon key="lpage">2362</infon><infon key="name_0">surname:Warzocha;given-names:K</infon><infon key="name_1">surname:Bienvenu;given-names:J</infon><infon key="name_2">surname:Ribeiro;given-names:P</infon><infon key="name_3">surname:Moullet;given-names:I</infon><infon key="name_4">surname:Dumontet;given-names:C</infon><infon key="name_5">surname:Neidhardt-Berard;given-names:EM</infon><infon key="name_6">surname:Coiffier;given-names:B</infon><infon key="name_7">surname:Salles;given-names:G</infon><infon key="pub-id_pmid">9649158</infon><infon key="section_type">REF</infon><infon key="source">Br J Cancer</infon><infon key="type">ref</infon><infon key="volume">77</infon><infon key="year">1998</infon><offset>16188</offset><text>Plasma levels of tumor necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.</text></passage><passage><infon key="fpage">2472</infon><infon key="lpage">2479</infon><infon key="name_0">surname:Kobayashi;given-names:D</infon><infon key="name_1">surname:Watanabe;given-names:N</infon><infon key="name_2">surname:Yamauchi;given-names:N</infon><infon key="name_3">surname:Tsuji;given-names:N</infon><infon key="name_4">surname:Sato;given-names:T</infon><infon key="name_5">surname:Niitsu;given-names:Y</infon><infon key="pub-id_pmid">9116291</infon><infon key="section_type">REF</infon><infon key="source">Blood</infon><infon key="type">ref</infon><infon key="volume">89</infon><infon key="year">1997</infon><offset>16329</offset><text> Endogenous tumor necrosis factor as a predictor of doxorubicin sensitivity in leukemia patients.</text></passage><passage><infon key="fpage">499</infon><infon key="lpage">508</infon><infon key="name_0">surname:Warzocha;given-names:K</infon><infon key="name_1">surname:Salles;given-names:G</infon><infon key="name_2">surname:Bienvenu;given-names:J</infon><infon key="name_3">surname:Bastion;given-names:Y</infon><infon key="name_4">surname:Dumontet;given-names:C</infon><infon key="name_5">surname:Renard;given-names:N</infon><infon key="name_6">surname:Neidhardt;given-names:EM</infon><infon key="name_7">surname:Coiffier;given-names:B</infon><infon key="pub-id_pmid">9053471</infon><infon key="section_type">REF</infon><infon key="source">J Clin Oncol</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">1997</infon><offset>16427</offset><text> The tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.</text></passage><passage><infon key="fpage">353</infon><infon key="name_0">surname:Wilson;given-names:AG</infon><infon key="name_1">surname:di Giovine;given-names:FS</infon><infon key="name_2">surname:Blakemore;given-names:AIF</infon><infon key="name_3">surname:Duff;given-names:GW</infon><infon key="pub-id_pmid">1363876</infon><infon key="section_type">REF</infon><infon key="source">Hum Mol Genet</infon><infon key="type">ref</infon><infon key="volume">1</infon><infon key="year">1992</infon><offset>16529</offset><text> Single base polymorphism in the human tumor necrosis factor alpha (TNF&#945;) gene detectable by NcoI restriction of PCR product.</text></passage><passage><infon key="fpage">562</infon><infon key="lpage">566</infon><infon key="name_0">surname:Abraham;given-names:LJ</infon><infon key="name_1">surname:Kroeger;given-names:KM</infon><infon key="pub-id_pmid">10534109</infon><infon key="section_type">REF</infon><infon key="source">JLeukoc Biol</infon><infon key="type">ref</infon><infon key="volume">66</infon><infon key="year">1999</infon><offset>16659</offset><text> Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease.</text></passage><passage><infon key="fpage">209</infon><infon key="lpage">219</infon><infon key="name_0">surname:Messer;given-names:G</infon><infon key="name_1">surname:Spengler;given-names:U</infon><infon key="name_2">surname:Jung;given-names:MC</infon><infon key="name_3">surname:Honold;given-names:G</infon><infon key="name_4">surname:Bl&#246;mer;given-names:K</infon><infon key="name_5">surname:Pape;given-names:GR</infon><infon key="name_6">surname:Riethm&#252;ller;given-names:G</infon><infon key="name_7">surname:Weiss;given-names:EH</infon><infon key="pub-id_pmid">1670638</infon><infon key="section_type">REF</infon><infon key="source">J Exp Med</infon><infon key="type">ref</infon><infon key="volume">173</infon><infon key="year">1991</infon><offset>16778</offset><text> Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production.</text></passage><passage><infon key="fpage">3574</infon><infon key="lpage">3581</infon><infon key="name_0">surname:Warzocha;given-names:K</infon><infon key="name_1">surname:Ribeiro;given-names:P</infon><infon key="name_2">surname:Bienvenu;given-names:J</infon><infon key="name_3">surname:Roy;given-names:P</infon><infon key="name_4">surname:Charlot;given-names:C</infon><infon key="name_5">surname:Rigal;given-names:D</infon><infon key="name_6">surname:Coiffier;given-names:B</infon><infon key="name_7">surname:Salles;given-names:G</infon><infon key="pub-id_pmid">9572991</infon><infon key="section_type">REF</infon><infon key="source">Blood</infon><infon key="type">ref</infon><infon key="volume">91</infon><infon key="year">1998</infon><offset>17007</offset><text> Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome.</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">12</infon><infon key="name_0">surname:Wilson;given-names:AG</infon><infon key="name_1">surname:di Giovine;given-names:FS</infon><infon key="name_2">surname:Duff;given-names:GW</infon><infon key="pub-id_pmid">7583349</infon><infon key="section_type">REF</infon><infon key="source">J Inflamm</infon><infon key="type">ref</infon><infon key="volume">45</infon><infon key="year">1995</infon><offset>17107</offset><text> Genetics of tumor necrosis factor-&#945; in autoimmune, infectious, and neoplastic diseases.</text></passage><passage><infon key="fpage">878</infon><infon key="lpage">880</infon><infon key="name_0">surname:Nadel;given-names:S</infon><infon key="name_1">surname:Newport;given-names:MJ</infon><infon key="name_2">surname:Booy;given-names:R</infon><infon key="name_3">surname:Levin;given-names:M</infon><infon key="pub-id_pmid">8843235</infon><infon key="section_type">REF</infon><infon key="source">J Infect Dis</infon><infon key="type">ref</infon><infon key="volume">174</infon><infon key="year">1996</infon><offset>17200</offset><text> Variation in the tumor necrosis factor-&#945; gene promoter region may be associated with death from meningococcal disease.</text></passage><passage><infon key="fpage">381</infon><infon key="lpage">384</infon><infon key="name_0">surname:St&#252;ber;given-names:F</infon><infon key="name_1">surname:Petersen;given-names:M</infon><infon key="name_2">surname:Bokelmami;given-names:F</infon><infon key="name_3">surname:Schade;given-names:U</infon><infon key="pub-id_doi">10.1097/00003246-199603000-00004</infon><infon key="pub-id_pmid">8625623</infon><infon key="section_type">REF</infon><infon key="source">Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">1996</infon><offset>17324</offset><text>A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis.</text></passage><passage><infon key="fpage">1259</infon><infon key="lpage">1264</infon><infon key="name_0">surname:Cabrera;given-names:M</infon><infon key="name_1">surname:Shaw;given-names:MA</infon><infon key="name_2">surname:Sharples;given-names:C</infon><infon key="name_3">surname:Williams;given-names:H</infon><infon key="name_4">surname:Castes;given-names:M</infon><infon key="name_5">surname:Convit;given-names:J</infon><infon key="name_6">surname:Blackwell;given-names:JM</infon><infon key="pub-id_pmid">7595196</infon><infon key="section_type">REF</infon><infon key="source">J Exp Med</infon><infon key="type">ref</infon><infon key="volume">182</infon><infon key="year">1995</infon><offset>17491</offset><text> Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis.</text></passage><passage><infon key="fpage">107</infon><infon key="lpage">112</infon><infon key="name_0">surname:Demeter;given-names:J</infon><infon key="name_1">surname:Porzsolt;given-names:F</infon><infon key="pub-id_doi">10.1046/j.1365-2141.1997.9912636.x</infon><infon key="pub-id_pmid">9136948</infon><infon key="section_type">REF</infon><infon key="source">Br J Haematol</infon><infon key="type">ref</infon><infon key="volume">97</infon><infon key="year">1997</infon><offset>17581</offset><text> Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia.</text></passage><passage><infon key="fpage">3122</infon><infon key="lpage">3133</infon><infon key="name_0">surname:Reiter;given-names:A</infon><infon key="name_1">surname:Schrappe;given-names:M</infon><infon key="name_10">surname:Odenwald;given-names:E</infon><infon key="name_11">surname:Ritter;given-names:J</infon><infon key="name_12">surname:Mann;given-names:G</infon><infon key="name_13">surname:Welte;given-names:K</infon><infon key="name_14">surname:Gadner;given-names:H</infon><infon key="name_15">surname:Riehm;given-names:H</infon><infon key="name_2">surname:Ludwig;given-names:W-D</infon><infon key="name_3">surname:Hiddemann;given-names:W</infon><infon key="name_4">surname:Sauter;given-names:S</infon><infon key="name_5">surname:Henze;given-names:G</infon><infon key="name_6">surname:Zimmermann;given-names:M</infon><infon key="name_7">surname:Lampert;given-names:F</infon><infon key="name_8">surname:Havers;given-names:W</infon><infon key="name_9">surname:Niethammer;given-names:D</infon><infon key="pub-id_pmid">7949185</infon><infon key="section_type">REF</infon><infon key="source">Blood</infon><infon key="type">ref</infon><infon key="volume">84</infon><infon key="year">1994</infon><offset>17693</offset><text> Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.</text></passage><passage><infon key="fpage">3310</infon><infon key="lpage">3322</infon><infon key="name_0">surname:Schrappe;given-names:M</infon><infon key="name_1">surname:Reiter;given-names:A</infon><infon key="name_10">surname:Kornhuber;given-names:B</infon><infon key="name_11">surname:Ritter;given-names:J</infon><infon key="name_12">surname:Welte;given-names:K</infon><infon key="name_13">surname:Gadner;given-names:H</infon><infon key="name_14">surname:Riehm;given-names:H</infon><infon key="name_2">surname:Ludwig;given-names:W-D</infon><infon key="name_3">surname:Harbott;given-names:J</infon><infon key="name_4">surname:Zimmermann;given-names:M</infon><infon key="name_5">surname:Hiddemann;given-names:W</infon><infon key="name_6">surname:Niemeyer;given-names:CM</infon><infon key="name_7">surname:Henze;given-names:G</infon><infon key="name_8">surname:Feldges;given-names:A</infon><infon key="name_9">surname:Zintl;given-names:F</infon><infon key="pub-id_pmid">10828010</infon><infon key="section_type">REF</infon><infon key="source">Blood</infon><infon key="type">ref</infon><infon key="volume"> 95</infon><infon key="year">2000</infon><offset>17835</offset><text> Improved outcome in childhood ALL despite reduced use of anthracyclines and of cranial radiotherapy: results of trial ALL-BFM 90.</text></passage><passage><infon key="fpage">1222</infon><infon key="lpage">1228</infon><infon key="name_0">surname:Stanulla;given-names:M</infon><infon key="name_1">surname:Schrappe;given-names:M</infon><infon key="name_2">surname:Brechlin;given-names:AM</infon><infon key="name_3">surname:Zimmermann;given-names:M</infon><infon key="name_4">surname:Welte;given-names:K</infon><infon key="pub-id_pmid">10666194</infon><infon key="section_type">REF</infon><infon key="source">Blood</infon><infon key="type">ref</infon><infon key="volume">95</infon><infon key="year">2000</infon><offset>17966</offset><text> Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study.</text></passage></document></collection>